York Charles N Ii - Net Worth and Insider Trading
York Charles N Ii Net Worth
The estimated net worth of York Charles N Ii is at least $3 Million dollars as of 2024-10-10. York Charles N Ii is the COO, CFO AND SECRETARY of Day One Biopharmaceuticals Inc and owns about 232,485 shares of Day One Biopharmaceuticals Inc (DAWN) stock worth over $3 Million. York Charles N Ii is also the CFO and VP of Spyre Therapeutics Inc and owns about 1,391 shares of Spyre Therapeutics Inc (SYRE) stock worth over $37,682. Details can be seen in York Charles N Ii's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that York Charles N Ii has not made any transactions after 2024-08-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of York Charles N Ii
York Charles N Ii Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, York Charles N Ii owns 2 companies in total, including Spyre Therapeutics Inc (SYRE) , and Day One Biopharmaceuticals Inc (DAWN) .
Click here to see the complete history of York Charles N Ii’s form 4 insider trades.
Insider Ownership Summary of York Charles N Ii
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SYRE | Spyre Therapeutics Inc | 2017-12-05 | Chief Financial Officer and VP |
| DAWN | Day One Biopharmaceuticals Inc | 2024-08-16 | COO & CFO and Secretary |
York Charles N Ii Latest Holdings Summary
York Charles N Ii currently owns a total of 2 stocks. Among these stocks, York Charles N Ii owns 232,485 shares of Day One Biopharmaceuticals Inc (DAWN) as of August 16, 2024, with a value of $3 Million and a weighting of 98.84%. York Charles N Ii also owns 1,391 shares of Spyre Therapeutics Inc (SYRE) as of December 5, 2017, with a value of $37,682 and a weighting of 1.16%.
Latest Holdings of York Charles N Ii
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| DAWN | Day One Biopharmaceuticals Inc | 2024-08-16 | 232,485 | 13.78 | 3,203,643 |
| SYRE | Spyre Therapeutics Inc | 2017-12-05 | 1,391 | 27.09 | 37,682 |
Holding Weightings of York Charles N Ii
York Charles N Ii Form 4 Trading Tracker
According to the SEC Form 4 filings, York Charles N Ii has made a total of 21 transactions in Day One Biopharmaceuticals Inc (DAWN) over the past 5 years, including 0 buys and 21 sells. The most-recent trade in Day One Biopharmaceuticals Inc is the sale of 2,633 shares on August 16, 2024, which brought York Charles N Ii around $36,862.
According to the SEC Form 4 filings, York Charles N Ii has made a total of 0 transactions in Spyre Therapeutics Inc (SYRE) over the past 5 years. The most-recent trade in Spyre Therapeutics Inc is the acquisition of 1,038 shares on December 5, 2017, which cost York Charles N Ii around $116,296.
Insider Trading History of York Charles N Ii
- 1
York Charles N Ii Trading Performance
GuruFocus tracks the stock performance after each of York Charles N Ii's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by York Charles N Ii is 62.24%. GuruFocus also compares York Charles N Ii's trading performance to market benchmark return within the same time period. The performance of stocks bought by York Charles N Ii within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how York Charles N Ii's insider trading performs compared to the benchmark.
Performance of York Charles N Ii
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 16.46 | | | | | |
| Relative Return to S&P 500(%) | 12.14 | | | | | |
York Charles N Ii Ownership Network
York Charles N Ii Owned Company Details
What does Spyre Therapeutics Inc do?
Who are the key executives at Spyre Therapeutics Inc?
York Charles N Ii is the Chief Financial Officer and VP of Spyre Therapeutics Inc. Other key executives at Spyre Therapeutics Inc include Chief Financial Officer Scott L Burrows , See Remarks Heidy King-jones , and director & 10 percent owner Fairmount Healthcare Co-invest L.p. .
Spyre Therapeutics Inc (SYRE) Insider Trades Summary
Over the past 18 months, York Charles N Ii made no insider transaction in Spyre Therapeutics Inc (SYRE). Other recent insider transactions involving Spyre Therapeutics Inc (SYRE) include a net sale of 18,531 shares made by Scott L Burrows ,
In summary, during the past 3 months, insiders sold 18,531 shares of Spyre Therapeutics Inc (SYRE) in total and bought 0 shares, with a net sale of 18,531 shares. During the past 18 months, 18,531 shares of Spyre Therapeutics Inc (SYRE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 18,531 shares.
Spyre Therapeutics Inc (SYRE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Spyre Therapeutics Inc Insider Transactions
York Charles N Ii Mailing Address
Above is the net worth, insider trading, and ownership report for York Charles N Ii. You might contact York Charles N Ii via mailing address: 901 S. Mopac Expressway, Barton Oaks Plaza One, Suite 250, Austin Tx 78746.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
